ESRD Clinical Trial
Official title:
Adding Urea to the Final Dialysis Fluid in Order to Prevent Dialysis Disequilibrium in Patients Who Need Aggressive Dialysis for Electrolyte Abnormalities
At times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (BUN) concentrations. These patients cannot be dialyzed aggressively as the lowering of serum BUN may results in disequilibrium syndrome but on the other hand they need aggressive dialysis in order to lower their serum potassium or fix their severe acidosis. If one is able to add urea to the dialysis fluid, one can prevent the rapid lowering of serum BUN and osmolality at the same time as doing aggressive dialysis to lower serum potassium and/or fix the metabolic acidosis.
Ure-Na 15 gram tablets would be used to add to the dialysis fluid How much urea to add would be a simple calculation based on the 45X dialysis system and the patients serum urea concentration. The dialysate fluid urea concentration would be made to be about 15-40 mg/dL lower than the serum concentration. The patients labs/vitals and symptoms would be closely monitored throughout the dialysis treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT03943212 -
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
|
N/A | |
Completed |
NCT03456648 -
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
|
Phase 2 | |
Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00294502 -
Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
|
Phase 4 | |
Completed |
NCT05011136 -
Physician Reimbursement Home Patients
|
||
Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
Completed |
NCT02278562 -
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
|
Phase 2 | |
Completed |
NCT01424787 -
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
|
N/A | |
Terminated |
NCT00580762 -
Bariatric Surgery for ESRD Patients vs Control
|
N/A | |
Recruiting |
NCT05339139 -
SAfety of Regional Citrate Anticoagulation (SARCA Study)
|
Phase 3 | |
Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
Recruiting |
NCT05309785 -
Safety and Efficacy of Canagliflozin in Advanced CKD
|
Phase 4 | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Not yet recruiting |
NCT02596386 -
Examination of Potassium Levels in Saliva in ESRD Patients
|
N/A | |
Active, not recruiting |
NCT02270515 -
Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease
|
N/A | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A |